Medical devices, healthcare technology and the business of care
510(k) clearance · K261715

Emboliner Embolic Protection System (EPC-03)

Emboline, Inc. · Decision date Sep 8, 2026

MEDTECHLEDGER EXPLANATIONK261715

What did the FDA decide?

The FDA recorded a substantially equivalent (SESE) decision on 2026-09-08 for the Emboliner Embolic Protection System (EPC-03), submitted by Emboline, Inc. of Santa Cruz, California, under 510(k) number K261715. The device falls under classification name Temporary Catheter, Embolic Protection, Transcatheter Intracardiac Procedures, regulation number 870.1251, product code PUM, with a Cardiovascular medical specialty and review panel. The application was received on 05/22/2026.

A SESE decision is a 510(k) clearance, not a premarket approval. The record lists the submission as Traditional, notes it was not reviewed by a third party, identifies it as a combination product, and states that no Predetermined Change Control Plan was authorized. A clinical trial, NCT05684146, is referenced. The page does not describe the device's components, indications, or performance data, and no summary statement is included in the public information, so those details remain unknown here.

The public record does not state the predicate device or the basis for the equivalence determination, and it does not address clinical outcomes. Readers should not infer efficacy, patient-selection criteria, or labeling content from this clearance entry.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Sep 8, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261715
Regulatory pathway
510(k) premarket notification
Product code
PUM
Decision code
SESE
Decision date
Sep 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Temporary Catheter, Embolic Protection, Transcatheter Intracardiac Procedures.

Product code
PUM
FDA device class
2

FDA decision timeline

  1. K261715 received

    Application receipt date recorded by FDA.

  2. K261715 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Emboline, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Santa Cruz, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records